Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript [Seeking Alpha]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Seeking Alpha
Company Participants Brendan Strong - Senior Vice President of Investor Relations Richard Paulson - President, CEO & Director Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Conference Call Participants John Mascarenhas Edward Tenthoff - Piper Sandler & Co., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Brian Abrahams - RBC Capital Markets, Research Division Ioannis Souroutzidis - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Albert Agustinus - Leerink Partners LLC, Research Division Michael King - Rodman & Renshaw Research Presentation Operator Good morning. My name is Jenny, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow. Please be advised tha
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics (KPTI) had its price target lowered by Robert W. Baird from $21.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Karyopharm Therapeutics (KPTI) had its price target lowered by HC Wainwright from $15.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Karyopharm myeloma drug yields mixed data in myelofibrosis trial [Yahoo! Finance]Yahoo! Finance
- Karyopharm Therapeutics jumps 18%, raises $30M privately [Seeking Alpha]Seeking Alpha
- Karyopharm Announces $30 Million Private Placement with RA Capital [TheStreet.com]TheStreet.com
KPTI
Earnings
- 2/12/26 - Miss
KPTI
Sec Filings
- 3/24/26 - Form 8-K
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- KPTI's page on the SEC website